STOCK TITAN

iSpecimen (ISPC) Stock News

ISPC NASDAQ

iSpecimen Inc. reports developments tied to its online marketplace for human biospecimens, which connects life science researchers with a network of healthcare specimen providers. Company updates cover biospecimen sourcing for research projects, supplier-network responsiveness, direct-to-customer shipping, and marketplace technology used to match customer requests with available inventory.

Recurring news themes include AI-assisted inventory matching, SalesStack marketplace integration, respiratory and other specimen procurement, international sourcing relationships, and capital-structure actions such as the completed reverse stock split of ISPC common stock.

Rhea-AI Summary

iSpecimen (NASDAQ: ISPC) completed its acquisition of two artificial intelligence products from Foldlab AI on November 2, 2026, expanding beyond its biospecimen marketplace.

The products identify disease-associated proteins and predict and monitor disease trends. The acquisition includes software, source code, model weights, data rights and related intellectual property. The $4.5 million purchase price comprises $750,000 cash paid at closing, up to $1.25 million in milestone payments and $2.5 million in common stock. The 2,907,977 shares were issued November 5, 2026, with a five-year trading restriction and lock-up with no leak-out. Two $625,000 milestone payments depend on delivery and acceptance under specified testing procedures. Stockholders approved the acquisition October 9, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary

iSpecimen (ISPC) expanded access to healthy donor whole blood through an existing collection partner and plans AI-powered customer search capabilities.

The fully consented blood is collected specifically for research and generally ships from the collection site on collection day, with the aim of enabling next-day delivery. Donor criteria, associated data and collection requirements can be tailored to individual studies. The partner can facilitate project-specific institutional review board review and approval and support repeat collections. iSpecimen already uses AI to review requests and identify potential network matches; the planned search capabilities are intended to improve customer searches of its inventory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
AI
-
Rhea-AI Summary

iSpecimen (ISPC) is coordinating more than 1,700 specimens for a hospital’s validation of a new chemistry analyzer. It identified a healthcare system already using the analyzer to help fulfill the collection. The specimens include serum, plasma, cerebrospinal fluid and urine, spanning different analytes and test-result ranges. Collection remains ongoing, with iSpecimen managing the project between the organizations. The hospital will use the specimens to complete validation before beginning clinical testing with the analyzer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
Rhea-AI Summary

iSpecimen (Nasdaq: ISPC) reported the completion of a large-scale international cancer research order involving hundreds of cancer blood specimens, shipped within three weeks of receiving the purchase order. The company used its global network of healthcare institutions, labs, biobanks, and research partners to source, collect, and internationally fulfill specialized cancer biospecimens, including FFPE and flash-frozen tissue, highlighting its focus on rapid, efficient biospecimen sourcing for time-sensitive research projects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.55%
Tags
none
-
Rhea-AI Summary

iSpecimen (Nasdaq: ISPC) announced the closing of its previously announced public offering totaling approximately $5.0 million in aggregate purchase price. The transaction includes 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 additional common shares.

According to iSpecimen, net proceeds are intended for repayment of outstanding liabilities, potential acquisitions or investments in businesses, products and technologies, marketing and advertising services, and general working capital. E.F. Hutton & Co. acted as exclusive placement agent. The securities were offered under an effective Form S-1 registration statement (File No. 333-297001) declared effective on July 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags
-
Rhea-AI Summary

iSpecimen (Nasdaq: ISPC) priced a public offering of approximately $5 million of common stock and/or pre-funded warrants at a public offering price of $1.30 per share, or $1.2999 per pre-funded warrant, reflecting the $0.0001 per share exercise price of each pre-funded warrant.

According to iSpecimen, net proceeds are expected to be used to repay outstanding liabilities, fund potential asset or business acquisitions, support investments in products and technologies, and pay for marketing and advertising services, with the remainder allocated to working capital. E.F. Hutton & Co. is acting as exclusive placement agent. The offering is expected to close on August 7, 2026, subject to customary conditions, under an effective SEC Form S‑1 registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.58%
Tags
Rhea-AI Summary

iSpecimen (Nasdaq: ISPC) priced a private placement for aggregate gross proceeds of approximately $2.5 million, issuing 488,281 common shares at $5.12 per share and offering pre-funded warrants at $5.1199 where exercisable for one share at $0.0001 per share.

The company intends to use net proceeds for working capital, including up to $900,000 for marketing. The offering is expected to close on or about May 11, 2026, is capped at 19.99% of outstanding shares pending stockholder approval, and E.F. Hutton serves as placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
private placement
-
Rhea-AI Summary

iSpecimen (NASDAQ: ISPC) will effect a 1-for-40 reverse stock split effective 4:30 p.m. ET on April 27, 2026, with split-adjusted trading beginning on April 28, 2026. The company will retain the ticker ISPC and receive new CUSIP 45032V306.

Outstanding shares will be reduced from 52,639,796 to 1,316,032. Options, warrants, RSUs and plan reserves will be proportionally adjusted; fractional shares will be rounded up to whole shares at the participant level. The company said the split is intended to raise the per-share trading price and help satisfy Nasdaq minimum bid requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.61%
Tags
-
Rhea-AI Summary

iSpecimen (NASDAQ: ISPC) implemented a direct shipping model that cuts human biospecimen transit times by ~70–85% and enables domestic deliveries in as little as 1–2 days.

The change reduces reliance on central hubs, lowers shipping handoffs and costs, and pairs with strengthened European and Eastern European supplier partnerships to improve access to rare specimens and consistency for international requests.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
Rhea-AI Summary

iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone for influenza research on March 16, 2026, collecting approximately 500 influenza swab samples over several weeks to support a customer project.

The company also maintained supply of cerebrospinal fluid (CSF), and noted rising demand for FFPE and fresh frozen tissue. Customer feedback praised specimen quality and documentation, with one customer indicating intent to credit iSpecimen as the sample source in publications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.87%
Tags
none

FAQ

What is the current stock price of iSpecimen (ISPC)?

iSpecimen (ISPC) last closed at $0.5961.

What is the market cap of iSpecimen (ISPC)?

The market cap of iSpecimen (ISPC) is approximately $1.5M.